MCHB
Mechanics Bank
There isn't enough reported data to score MCHB yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
MCHB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
MCHB's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like MCHB.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
MCHB PE Valuation
MCHB has no meaningful PE right now: it lost money over the past year.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
MCHB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect MCHB's revenue to grow, with its earnings and profitability holding steady.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
MCHB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.07 | — |
| Q3 2024 | -$1.30 | -$0.48 |
| Q2 2024 | -$0.79 | -664% |
| Q1 2024 | -$2.13 | -177% |
| Q4 2023 | -$1.46 | -142% |
| Q3 2023 | -$0.82 | -118% |
| Q2 2023 | $0.14 | -97% |
| Q1 2023 | $2.75 | -46% |
| Q4 2022 | $3.49 | -36% |
MS has the stronger earnings trend. Trailing diluted EPS is down 259% for MCHB versus MS up 29%.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
MCHB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $161.5M | -37% |
| Q2 2026 | $201M | +310% |
| Q1 2026 | $200.1M | +341% |
| Q3 2025 | $255.4M | +544% |
| Q2 2025 | $49M | +14% |
| Q1 2025 | $45.4M | +9% |
| Q3 2024 | $39.7M | -20% |
| Q2 2024 | $42.9M | -20% |
MCHB's revenue is growing: $161M last quarter, down 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +21 points |
| Q2 2026 | 39% | +49 points |
| Q1 2026 | 31% | +41 points |
| Q4 2025 | 59% | N/A |
| Q3 2025 | 18% | +42 points |
| Q2 2025 | -9.8% | +8.9 points |
| Q1 2025 | -10% | +15 points |
| Q3 2024 | -24% | -27 points |
MCHB has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over MCHB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
MCHB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | -76% |
| Q2 2026 | $49.6M | +$59.5M |
| Q1 2026 | $8.8M | +$31.3M |
| Q3 2025 | $109.1M | +$126.6M |
| Q2 2025 | -$9.9M | +$12.2M |
| Q1 2025 | -$22.6M | -$8.7M |
| Q3 2024 | -$17.5M | -161% |
| Q2 2024 | -$22M | -213% |
MCHB has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
MCHB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +0.3% | +63.9K shares |
| 3 years | -4.4% | -871K shares |
| 5 years | -21% | -4.9M shares |
MCHB has 19M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $75M |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over MCHB on shareholder dilution, with a more favorable share count trend.
MCHB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2023 | 128.7x | High |
| Q1 2023 | 22.9x | High |
| Q4 2022 | 12.4x | High |
| Q3 2022 | 14.3x | High |
| Q2 2022 | 12.4x | High |
| Q1 2022 | 2.9x | Moderate |
| Q4 2021 | 0.7x | Very low |
MCHB has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
MCHB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 16.7 | Oversold |
MCHB's weekly RSI is 42 (neutral) and its Stochastic is 17 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
MCHB PE vs Financial Services Sector
| Metric | MCHB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
MCHB has no meaningful PE right now: it lost money over the past year.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
MCHB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.7 | 2.2% below |
| 20 week MA | $15.6 | 7.5% below |
| 50 week MA | $15.2 | 5.1% below |
| 100 week MA | $13.6 | 5.7% above |
| 200 week MA | $13.0 | 11% above |
MCHB has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 11% above its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over MCHB on trend strength, trading above more of its moving averages.
MCHB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $33.5 | -0.9% |
| 2021 | $33.5 | $51.4 | +53% |
| 2022 | $51.4 | $27.0 | -47% |
| 2023 | $27.0 | $10.3 | -62% |
| 2024 | $10.3 | $11.2 | +8.3% |
| 2025 | $11.2 | $14.7 | +31% |
| 2026 YTD | $14.7 | $14.4 | -2% |
MCHB has finished lower in three of the last six years. It's down 2% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over MCHB on returns for 2026, with the stronger performance.